Form 4: Nuvalent Director Grant Bogle Acquires Equity Through Restricted Stock Units and Stock Options

Nuvalent, Inc. Director Grant C. Bogle has acquired 2,647 shares of Class A Common Stock via restricted stock units and 4,147 stock options, as reported in a recent SEC Form 4 filing.

Summary

• Grant C. Bogle, a Director of Nuvalent, Inc. (NUVL), acquired 2,647 shares of Class A Common Stock through restricted stock units (RSUs) on June 18, 2025.
• Each RSU represents the right to receive one share of Nuvalent, Inc. Class A Common Stock.
• These RSUs vest in full on the earlier of June 18, 2026, or the date of Nuvalent, Inc.'s next annual meeting of stockholders, subject to continued service.
• Following this transaction, Mr. Bogle beneficially owns 5,847 shares of Class A Common Stock directly.
• Mr. Bogle also acquired 4,147 stock options to buy Class A Common Stock on June 18, 2025, with an exercise price of $75.53 per share.
• The shares underlying these options vest in full on the earlier of June 18, 2026, or the date of Nuvalent, Inc.'s next annual meeting of stockholders, subject to continued service.
• The stock options have an expiration date of June 18, 2035.
• Following this transaction, Mr. Bogle beneficially owns 4,147 stock options directly.

Sentiment

Score: 6

Explanation: The document reports a routine equity grant to a director, which is a neutral to slightly positive event as it aligns the director's interests with shareholders. There are no negative implications or unexpected events reported.

Positives

• The acquisition of shares and options by a director aligns their interests with those of the shareholders, promoting long-term value creation.
• Equity grants are a standard component of executive and director compensation, indicating a commitment to retaining key personnel.

Future Outlook

The document indicates future vesting events for the granted equity, contingent on continued service to Nuvalent, Inc. through the specified dates or the next annual meeting.

Industry Context

This Form 4 filing represents a routine insider transaction where a director receives equity as part of their compensation package. Such grants are common practice across industries to incentivize long-term performance and align management interests with shareholder value, particularly in the biotechnology or pharmaceutical sector where long-term development cycles are prevalent.

Stakeholder Impact

• Shareholders: The equity grants align the director's financial interests with the long-term performance of the company, potentially benefiting shareholders through improved governance and strategic decisions.
• Employees: While not directly impacting all employees, the compensation structure for directors can reflect broader company policies on equity-based incentives.

Next Steps

• Vesting of 2,647 Restricted Stock Units on the earlier of June 18, 2026, or the date of Nuvalent, Inc.'s next annual meeting of stockholders.
• Vesting of 4,147 Stock Options on the earlier of June 18, 2026, or the date of Nuvalent, Inc.'s next annual meeting of stockholders.
• Potential exercise of stock options by Grant C. Bogle before the expiration date of June 18, 2035.

Key Dates

Keywords

Nuvalent Inc., NUVL, SEC Form 4, Insider Transaction, Equity Grant, Restricted Stock Units, Stock Options, Director Compensation, Beneficial Ownership